6.2 Multimodal Analgesia, Pain Scoring Scales & Local/Regional Anesthesia

Multimodal Analgesia, Pain Scoring Scales & Local/Regional Anesthesia

VTS Core Concept: Pain is not merely an uncomfortable sensation—untreated acute pain is a destructive systemic pathology. Pain induces severe neuroendocrine stress responses: massive endogenous catecholamine release, tachycardia, systemic vasoconstriction, hypermetabolism, protein catabolism, immunosuppression, impaired wound healing, and central nervous system remodeling. Multimodal analgesia—targeting multiple distinct points along the nociceptive pathway—is the cornerstone of emergency and critical care nursing.

---

1. The Physiology of Nociception

Nociception is the physiological process by which noxious thermal, mechanical, or chemical stimuli are detected, transmitted, and processed by the nervous system. It consists of four distinct phases:

[ Noxious Stimulus ]
        │
        ▼
1. TRANSDUCTION   ───► Peripheral nociceptors (A-delta & C fibers) convert stimulus into electrical action potentials
        │
        ▼
2. TRANSMISSION    ───► Action potentials propagate along peripheral nerves to the dorsal horn of the spinal cord
        │
        ▼
3. MODULATION      ───► Spinal dorsal horn interneurons amplify or inhibit signals (Substance P, Glutamate, NMDA)
        │
        ▼
4. PERCEPTION      ───► Thalamus and cerebral cortex process signals into the conscious, emotional experience of PAIN

The Four Phases and Pharmacological Targets

2. Central Sensitization & The "Wind-Up" Phenomenon

When surgical trauma or tissue inflammation generates severe, repetitive, uninhibited C-fiber nociceptive volleys into the dorsal horn of the spinal cord, a profound neuroplastic alteration occurs known as central sensitization (or the "wind-up" phenomenon):

1. Glutamate Release: Intense nociceptive input causes massive presynaptic release of excitatory amino acids (Glutamate) and neuropeptides (Substance P).
2. Removal of Magnesium Block: Under resting conditions, post-synaptic N-methyl-D-aspartate (NMDA) receptor channels are blocked by a resting magnesium (Mg2+) ion. Sustained membrane depolarization by glutamate acting at AMPA receptors expels the Mg2+ plug from the NMDA receptor pore.
3. Calcium Influx & Second Messengers: Unblocked NMDA receptors allow a massive influx of intracellular calcium (Ca2+), activating protein kinase C (PKC), nitric oxide synthase (NOS), and cyclooxygenase-2 (COX-2) gene transcription.
4. Hyperexcitability & Receptive Field Expansion: Dorsal horn wide dynamic range (WDR) neurons become profoundly hyperexcitable, firing in response to sub-threshold inputs.

Clinical Manifestations of Central Sensitization

• Primary Hyperalgesia: Exaggerated pain response to normally painful stimuli at the site of tissue injury.
• Secondary Hyperalgesia: Pain sensitivity expanding into undamaged, healthy surrounding tissue.
• Allodynia: Pain evoked by normally non-noxious, innocuous stimuli (such as light touch, gentle palpation, or air movement).
• Opioid Resistance: Established wind-up requires dramatically escalating doses of opioids to achieve clinical comfort, frequently producing dysphoria and side effects without pain relief. Subanesthetic Ketamine (0.1-0.5 mg/kg IV bolus, followed by 2-10 mcg/kg/min CRI) directly blocks open NMDA receptor channels, "unwinding" central sensitization and restoring opioid receptor sensitivity.

---

3. Validated Veterinary Pain Scoring Scales

Pain assessment in veterinary patients requires systematic, validated behavioral evaluation tools rather than subjective guesswork.

1. Glasgow Composite Measure Pain Scale Short Form (CMPS-SF)

The Glasgow CMPS-SF is a validated behavioral assessment tool for acute pain in dogs. It evaluates 6 categories comprising 30 behavioral descriptions:

• Evaluated Categories: (1) Vocalization, (2) Attention to wound/surgical site, (3) Demeanor/responsiveness, (4) Mobility/gait, (5) Posture, and (6) Response to gentle palpation around the wound.
• Scoring Scale: Total maximum score of 24 for ambulatory dogs (or 20 for non-ambulatory dogs).
• Analgesic Intervention Threshold:
  • For ambulatory dogs: Score >= 6 / 24 mandates immediate analgesic intervention/rescue.
  • For non-ambulatory dogs: Score >= 5 / 20 mandates immediate analgesic intervention/rescue.

2. Colorado State University (CSU) Pain Scales (Canine & Feline)

The CSU Pain Scale uses a 0 to 4 numerical rating scale integrated with behavioral descriptions and anatomical diagrams:

• Score 0 (No Pain): Happy, content, relaxed body posture, interactive, non-reactive to wound palpation.
• Score 1 (Mild Pain): Mildly quiet or restless, subtle facial tension, whimpering/withdrawing slightly on firm wound palpation.
• Score 2 (Moderate Pain): Drooped head, looking at or licking wound, guarding affected area, vocalizing on palpation, tense abdomen.
• Score 3 (Severe Pain): Depressed, reluctant to move, groaning, vocalizing, dramatic guarding or flinching upon palpation, glazed expression.
• Score 4 (Excruciating Pain): Prostrate, thrashing, screaming/crying, completely unresponsive to human contact, extreme aggression on approach.
• Intervention Threshold: Any score of >= 2 / 4 warrants reassessment and immediate analgesic rescue.

3. Feline Grimace Scale (FGS)

The Feline Grimace Scale evaluates 5 facial action units (ear position, orbital tightening, muzzle tension, whisker position, and head position), scored from 0 (absent) to 2 (markedly present) with a maximum total of 10. An overall score of >= 4 / 10 (or >= 0.39 normalized) indicates that the cat requires analgesic rescue.

---

4. Systemic Multimodal Analgesic Pharmacology

1. Opioid Class Dynamics

• Pure mu-Agonists (Morphine, Hydromorphone, Methadone, Fentanyl): Provide maximum efficacy for moderate-to-severe somatic and visceral pain. No analgesic "ceiling effect."
• Partial mu-Agonists (Buprenorphine 0.01-0.03 mg/kg IV/IM/OTM): Extremely high binding affinity for mu-receptors but lower intrinsic efficacy. Possesses an analgesic ceiling effect—increasing the dose beyond therapeutic range does not produce additional analgesia. Excellent for mild-to-moderate feline pain (transmucosal OTM absorption). Clinical Warning: Due to its near-irreversible binding affinity, buprenorphine will displace pure mu-agonists and block their efficacy if emergency rescue analgesia is needed.
• kappa-Agonists / mu-Antagonists (Butorphanol 0.1-0.4 mg/kg IV/IM): Stimulates kappa receptors (mild visceral sedation/analgesia) while antagonizing mu receptors. Has a short duration of analgesia (45-90 minutes) and poor somatic pain efficacy. Useful for non-painful diagnostic sedation or as a partial reversal agent for opioid-induced dysphoria/respiratory depression while maintaining mild kappa analgesia.

2. Alpha-2 Adrenergic Agonists (Dexmedetomidine)

Acts at presynaptic alpha-2-receptors in the locus coeruleus (sedation) and dorsal horn substantia gelatinosa (analgesia). Micro-doses (0.5-1.0 mcg/kg IV) provide potent opioid-sparing analgesia and smooth emergence delirium without catastrophic vasoconstriction.

3. Local Anesthetics (Sodium Channel Blockers)

Reversibly bind to the intracellular pore of voltage-gated sodium channels (NaV), preventing sodium influx and completely abolishing action potential generation.

• Lidocaine: Rapid onset (2-5 min), duration 1-2 hours. Safe for systemic IV CRI in dogs.
• Bupivacaine (0.25-0.5%): Slow onset (15-20 min), long duration (4-8 hours). STRICTLY CONTRAINDICATED FOR INTRAVENOUS USE. IV injection causes catastrophic, refractory myocardial conduction blockade and cardiovascular collapse. Toxicity Treatment: 20% Intravenous Lipid Emulsion (ILE) (1.5 mL/kg bolus followed by 0.25 mL/kg/min CRI).
• Ropivacaine (0.5-0.75%): S-enantiomer, duration 4-6 hours. Significantly less cardiotoxic than bupivacaine; preferentially blocks sensory fibers over motor fibers.

4. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Inhibit Cyclooxygenase (COX-1/COX-2), blocking the conversion of arachidonic acid to inflammatory prostaglandins (PGE2).

Critical ECC Warning: NSAID Contraindications

NSAIDs are strictly contraindicated in the emergency/trauma setting when any of the following exist:

• Hypovolemia, Hypotension (MAP < 60 mmHg), or Dehydration (blocks renal prostaglandins PGE2/PGI2, triggering severe renal medullary ischemia and acute tubular necrosis)
• Acute Kidney Injury (AKI) or Chronic Renal Disease
• Gastrointestinal Ulceration, Hemorrhage, or Septic Peritonitis
• Concurrent Corticosteroid Therapy (requires a mandatory 5-7 day washout period to avoid catastrophic GI perforation)

---

5. Regional and Local Anesthesia Techniques in Critical Care

Regional anesthesia blocks nociceptive transmission at the level of peripheral nerve trunks or the spinal cord, achieving complete desensitization of the surgical field.